SCHEDULE 13D: Tang Capital Entities Disclose 9.8% Stake in HilleVax, Inc. for Investment Purposes

Tang Capital Management, Kevin Tang, and affiliated entities have filed a Schedule 13D, disclosing a beneficial ownership of 9.8% of HilleVax, Inc.'s common stock, acquired for investment purposes.

Summary

• The filing is a Schedule 13D by Tang Capital Management, LLC (TCM), Kevin Tang, Tang Capital Partners, LP (TCP), Tang Capital Partners International, LP (TCPI), Tang Capital Partners III, Inc., Tang Capital Partners IV, Inc., and Concentra Biosciences, LLC (collectively, the "Reporting Persons").
• The Reporting Persons beneficially own an aggregate of 4,920,000 shares of HilleVax, Inc.'s Common Stock, representing 9.8% of the outstanding shares.
• This percentage is based on 50,141,064 shares of Common Stock outstanding as of March 10, 2025, as reported in HilleVax's Annual Report on Form 10-K filed on March 28, 2025.
• The Common Stock was acquired using approximately $8.9 million of working capital set aside by TCP and TCPI for general investment purposes.
• The purpose of the acquisition is for investment, made in the Reporting Persons' ordinary course of business.
• The Reporting Persons continuously evaluate HilleVax, including its businesses, operations, and prospects.
• They may engage in discussions with HilleVax and its representatives and/or other stockholders, potentially seeking confidentiality agreements or discussing strategic alternatives or changes to operations.
• There have been no transactions in HilleVax's Common Stock by the Reporting Persons during the past 60 days.

Sentiment

Score: 7

Explanation: The filing indicates a significant investment by a reputable capital management firm, suggesting a positive view on HilleVax's prospects. The stated intent to engage in discussions about strategic alternatives could be seen as a positive catalyst. However, it also notes the possibility of disposing of shares, which introduces some uncertainty.

Positives

• A significant investment by Tang Capital entities, indicating a notable vote of confidence in HilleVax, Inc.'s prospects.
• The stated intent to continuously evaluate the Issuer and potentially engage in discussions regarding strategic alternatives or operational changes could lead to value-enhancing initiatives for HilleVax.
• The acquisition was made for investment purposes and in the ordinary course of business, suggesting a strategic and deliberate move by a sophisticated investor.

Risks

• The Reporting Persons may modify their ownership of Common Stock, including acquiring additional shares or disposing of some or all shares, which could introduce volatility or uncertainty regarding future share price movements.
• The use of commingled margin accounts by TCP and TCPI means positions are pledged as collateral, and accounts may have debit balances, although the specific amount of margin used for HilleVax stock is not determinable.

Future Outlook

The Reporting Persons continuously evaluate HilleVax, including its businesses, operations, and prospects. They may engage in discussions with the Issuer and other stockholders, potentially seeking confidentiality agreements or discussing strategic alternatives or changes to operations. They also retain the flexibility to modify their ownership of Common Stock, including acquiring additional shares or disposing of some or all shares, based on their assessment, prevailing market conditions, or other investment considerations.

Management Comments

• "The Reporting Persons purchased the Common Stock reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business."
• "As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects."
• "The Reporting Persons may engage in discussions with the Issuer and its representatives and/or other stockholders, seek to enter into a confidentiality agreement with the Issuer and/or discuss with the Issuer different strategic alternatives or changes to the Issuer's operations."
• "There can be no certainty as to whether discussions with the Issuer will occur, the outcome of any such discussions or whether the Reporting Persons will take any actions relating to the Issuer."
• "Subject to applicable law and regulation, the Reporting Persons may modify their ownership of the Common Stock, including acquiring additional Common Stock or disposing of some or all of the Common Stock beneficially owned by them."

Industry Context

This Schedule 13D filing represents a significant ownership disclosure by an investment firm in a publicly traded company, HilleVax, Inc., which operates in the biotechnology or pharmaceutical sector. Such filings are common in the financial markets and indicate a strategic investment interest by a substantial shareholder, often with an intent to engage with the company's management or board regarding its strategic direction.

Legal Proceedings

• During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
• During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment group with a stated intent to discuss strategic alternatives could signal potential future changes or increased scrutiny, which might be viewed positively or negatively depending on the nature of the changes. It also highlights a large block of shares held by a single group.
• Management/Board: HilleVax's management and board may face increased engagement or pressure from this significant shareholder, given the stated intent to discuss strategic alternatives or operational changes.

Next Steps

• Reporting Persons may engage in discussions with HilleVax and its representatives and/or other stockholders.
• Reporting Persons may seek to enter into a confidentiality agreement with HilleVax.
• Reporting Persons may discuss different strategic alternatives or changes to HilleVax's operations.
• Reporting Persons may modify their ownership of Common Stock, including acquiring additional shares or disposing of some or all shares.

Key Dates

Recommendation

Keywords

HilleVax, Tang Capital Management, Kevin Tang, Schedule 13D, beneficial ownership, common stock, investment, equity stake, SEC filing, biotechnology, pharmaceuticals